Bridgeway Capital Management’s Prelude Therapeutics PRLD Stock Holding History

Bridgeway Capital Management’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$183K	Hold	53,500	–	–	﹤0.01%	1051
2025 Q4	$155K	Hold	53,500	–	–	﹤0.01%	1060
2025 Q3	$77K	Sell	53,500 -35,000	-40%	-$35.1K	﹤0.01%	1133
2025 Q2	$71.6K	Hold	88,500	–	–	﹤0.01%	1108
2025 Q1	$68K	Sell	88,500 -22,500	-20%	-$21K	﹤0.01%	1097
2024 Q4	$142K	Sell	111,000 -65,100	-37%	-$86.4K	﹤0.01%	1060
2024 Q3	$365K	Buy	176,100 +52,500	+42%	+$243K	0.01%	932
2024 Q2	$471K	Hold	123,600	–	–	0.01%	871
2024 Q1	$586K	Sell	123,600 -25,149	-17%	-$97.8K	0.01%	880
2023 Q4	$635K	Buy	148,749 +111,800	+303%	+$340K	0.01%	881
2023 Q3	$114K	Hold	36,949	–	–	﹤0.01%	1200
2023 Q2	$166K	Hold	36,949	–	–	﹤0.01%	1176
2023 Q1	$211K	Hold	36,949	–	–	0.01%	1097
2022 Q4	$223K	Hold	36,949	–	–	0.01%	1065
2022 Q3	$244K	Sell	36,949 -10,000	-21%	-$67.4K	0.01%	1094
2022 Q2	$245K	Buy	+46,949	New	+$239K	0.01%	1048

Other funds holding PRLD

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Bridgeway Capital Management's PRLD Position: Q1 2026 in Review

Bridgeway Capital Management held its Prelude Therapeutics (PRLD) position steady in Q1 2026 at 53,500 shares worth $183K. The position accounts for ﹤0.01% of the portfolio, ranked #1051.

Bridgeway Capital Management first reported a position in PRLD in Q2 2022 and has held it in 16 quarters since. The position peaked at $635K in Q4 2023. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

Bridgeway Capital Management held 53,500 shares of Prelude Therapeutics worth $183K as of Q1 2026.
Bridgeway Capital Management left its Prelude Therapeutics share count unchanged in Q1 2026.
Prelude Therapeutics made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #1051 holding.
Bridgeway Capital Management first reported a position in Prelude Therapeutics in Q2 2022 and has held it in 16 quarters since.
Bridgeway Capital Management's Prelude Therapeutics position peaked at $635K in Q4 2023.
55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.